ABT vs SNGX · P/E 25, rev $44.33B vs $6.0M cap
Abbott Laboratories (ABT) versus Soligenix Inc. (SNGX) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Soligenix Inc. (SNGX) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
SNGX does not have a complete income-statement cache yet.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. SNGX currently screens at market cap $6.0M.
Not investment advice. Open the ABT and SNGX stock pages for the full models.
Not investment advice.